Bienstar Wellness Starts Treating Patients with PsychedelicAssisted Psychotherapy in Brazil by completing the Acquisition of BRC Saude Mental E Terapias Assistidas Ltda. focused on ibogaine treatment

• The Acquisition of BRC Saude Mental E Terapias Assistidas Ltda. provides Bienstar the entrance to Brazil, largest market in Latin America, with a population of 215M, where ketamine and ibogaine substances are regulated for medical use in psychotherapies.
• BRC conducts legal ibogaine and ketamine treatments in Brazil and operates under the Medical Directorship of Dr. Rasmussen who has 27 years of experience and has treated over 2,500 patients with psychedelic substances.

May 4, 2022 – Bienstar Wellness Corp. (“Bienstar” or the “Company”), an integrative mental health company specialized in psychedelic medicine, with its core operations in Latin America, is pleased to announce that the Company completed the acquisition of 100% of BRC Saude Mental E Terapias Assistidas Ltda. (¨BRC¨) a Brazilian company specialized in ibogaine treatments for substance abuse.

Brazil is the largest market in Latin America, with a population of 215M, where ketamine and ibogaine substances are legal for medical use in psychotherapies. Ibogaine use is regulated by national Decree, positioning Brazil as one of the few countries where ibogaine substance use is legal and regulated.

Marco Algorta, Bienstar Co-founder and CEO stated, ¨We are very excited with the completion of this acquisition which represents the Company Kick Off in Brazil by starting to treat our first patients with Psychedelic-Assisted Psychotherapy in the country though our subsidiary BRC Saude Mental E Terapias Assistidas Ltda.¨

About Bienstar Wellness Corp

Bienstar Wellness Corp. is a company focused on bringing alternative mental health treatments to Latin America. Bienstar will provide psychedelic assisted psychotherapy with approved substances, through a network of clinics across the region, including Brazil, Mexico, Perú, Uruguay and Panama where it will start treating patients with depression, mood disorders and substance abuse, affecting over 16.3 million people in Brazil.

Compliance is at the core of Bienstar’s values, and its operations are fully compliant with all local regulations.

Bienstar offers effective and safe Psychedelic-Assisted Psychotherapy protocols for the treatment of depression and other treatment-resistant mental health conditions, helping our patients build better and more fulfilling lives.

With a focused regional strategy and patient oriented approach, by merging medical and psychosocial treatment models with psychedelic-assisted therapies, Bienstar protocols will help patients overcome deep-rooted traumas and psychic issues behind problems such as substance abuse, chronic pain compulsions, and other complex treatment and origin conditions.

Bienstar is led by Co-founder and Chief Executive Officer, Marco Algorta, together with an experienced executive team, and a knowledgeable Board of Directors.

Further information on Bienstar can be found at

Contact Information:
Marco Algorta, CEO
Telephone: +598 99 118 628

Email: [email protected]

Investor Relations
Email: [email protected]

Forward-Looking Statements
This release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those
anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.